Scientists at the MUSC Hollings Cancer Center are making strides in combating medulloblastoma, the most common malignant pediatric brain tumor, by targeting the cells responsible for cancer relapse. While survival rates are generally favorable, about 30% of patients face a return of their cancer, with dire outcomes. Jezabel Rodriguez Blanco, Ph.D., leading the research, emphasizes the importance of addressing a subset of tumor cells that can self-renew and resist standard treatments. The study, published in *Cell Death & Disease*, explores the role of CK1α, a protein that influences two major cancer-signaling pathways: GLI and WNT. By utilizing pyrvinium, an FDA-approved drug, researchers found that it not only inhibits GLI but also targets WNT-driven self-renewal, thereby reducing the risk of relapse. Although the results are promising, Blanco cautions that further development is needed, particularly in modifying pyrvinium for effective delivery across the blood-brain barrier. This research aims to shift the focus from merely shrinking tumors to preventing their recurrence, potentially improving the quality of life for young patients.